About Innovus Pharmaceuticals (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
Industry, Sector and Symbol:
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:INNV
- Previous Symbol: NASDAQ:INNV
- CUSIP: N/A
- Web: www.innovuspharma.com
- Current Ratio: 0.64%
- Quick Ratio: 0.58%
Sales & Book Value:
- Annual Sales: $4.82 million
- Price / Sales: 2.98
- Book Value: $0.01 per share
- Price / Book: 8.75
- Trailing EPS: ($0.07)
- Net Income: ($13,700,000.00)
- Net Margins: -102.95%
- Return on Equity: -330.39%
- Return on Assets: -72.75%
- Employees: 5
- Outstanding Shares: 164,430,000
Frequently Asked Questions for Innovus Pharmaceuticals (OTCMKTS:INNV)
What is Innovus Pharmaceuticals' stock symbol?
Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."
How were Innovus Pharmaceuticals' earnings last quarter?
Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) announced its earnings results on Tuesday, November, 14th. The company reported ($0.01) earnings per share for the quarter. The business earned $2.22 million during the quarter. Innovus Pharmaceuticals had a negative net margin of 102.95% and a negative return on equity of 330.39%. View Innovus Pharmaceuticals' Earnings History.
Who are some of Innovus Pharmaceuticals' key competitors?
Some companies that are related to Innovus Pharmaceuticals include Tonix Pharmaceuticals Holding Corp. (TNXP), Trimel Pharmaceuticals Corp. (TRLPF), Cleveland BioLabs (CBLI), HTG Molecular Diagnostics (HTGM), Catalyst Biosciences (CBIO), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), Cellectar Biosciences (CLRB), Fibrocell Science (FCSC), Eleven Biotherapeutics (EBIO), Aviragen Therapeutics (AVIR), Biocept (BIOC), Check-Cap (CHEK), Soligenix (SNGX), Valeritas Holdings (VLRX), Eyegate Pharmaceuticals (EYEG), DelMar Pharmaceuticals (DMPI) and Argos Therapeutics (ARGS).
Who are Innovus Pharmaceuticals' key executives?
Innovus Pharmaceuticals' management team includes the folowing people:
- Henry J. Esber Ph.D., Chairman of the Board (Age 78)
- Bassam B. Damaj Ph.D., President, Chief Executive Officer, Director (Age 48)
- Rauly Gutierrez CPA, Principal Financial Officer, Principal Accounting Officer
- Randy J. Berholtz Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 53)
- Vivian H. Liu, Director (Age 55)
- Ziad Mirza M.D., Director (Age 54)
How do I buy Innovus Pharmaceuticals stock?
Shares of Innovus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovus Pharmaceuticals' stock price today?
One share of Innovus Pharmaceuticals stock can currently be purchased for approximately $0.09.
How big of a company is Innovus Pharmaceuticals?
Innovus Pharmaceuticals has a market capitalization of $14.39 million and generates $4.82 million in revenue each year. The company earns ($13,700,000.00) in net income (profit) each year or ($0.07) on an earnings per share basis. Innovus Pharmaceuticals employs 5 workers across the globe.
How can I contact Innovus Pharmaceuticals?
Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92122. The company can be reached via phone at 858-964-5123 or via email at email@example.com.
MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Innovus Pharmaceuticals (OTCMKTS:INNV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Innovus Pharmaceuticals (OTCMKTS:INNV)
Analysts' Ratings History for Innovus Pharmaceuticals (OTCMKTS:INNV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Innovus Pharmaceuticals (OTCMKTS:INNV)
Earnings History by Quarter for Innovus Pharmaceuticals (OTCMKTS INNV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017||Q3 2017||($0.01)||$2.22 million||View||N/A|
|8/14/2017||Q2 2017||($0.01)||$2.04 million||View||N/A|
|3/6/2017||Q4 2016||($0.02)||$1.69 million||View||N/A|
|11/10/2016||Q3 2016||($0.01)||$1.88 million||View||N/A|
Earnings Estimates for Innovus Pharmaceuticals (OTCMKTS:INNV)
Current Year EPS Consensus Estimate: $-0.06 EPS
Dividend History for Innovus Pharmaceuticals (OTCMKTS:INNV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Innovus Pharmaceuticals (OTCMKTS INNV)
Insider Ownership Percentage: 19.14%
Insider Trades by Quarter for Innovus Pharmaceuticals (OTCMKTS INNV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/12/2013||Bassam Damaj||CEO||Buy||416,841||$0.32||$133,389.12|| |
|2/2/2013||Bassam Damaj||CEO||Buy||250,406||$0.48||$120,194.88|| |
Latest Headlines for Innovus Pharmaceuticals (OTCMKTS INNV)
Innovus Pharmaceuticals (OTCMKTS INNV) Chart for Sunday, November, 19, 2017